Evidence map›Paper›PMID 34261902›Full record

ReviewCurrent opinion in infectious diseases2021

Coronavirus disease 2019 in children.

Emily R Levy, Jennifer Blumenthal, Kathleen Chiotos

Abstract readReview
In one paragraph

Review in Current opinion in infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Modeling COVID-19 Transmission Dynamics: A Bibliometric Review.International journal of environmental research and public health · 2022
    Review
  3. COVID-19 FAQs in Pediatric Cardiac Surgery: 2022 Perspective and Updates.World journal for pediatric & congenital heart surgery · 2022
    Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Emily R LevyDivision of Pediatric Infectious Diseases.
Jennifer BlumenthalDivision of Infectious Diseases, Department of Medicine.
Kathleen ChiotosDivision of Infectious Diseases, Department of Pediatrics.
Boston Children's Hospital · USChildren's Hospital of Philadelphia · USPediatric Infectious Diseases Society · US

Funding

Principal ProjectU19AI144301 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI Maria Virginia Pascual · 2019 to 2026
$9.9M
PEDSnet Scholars: A Training Program for Pediatric Learning Health System ResearchersK12HS026393 · AHRQ · CHILDREN'S HOSP OF PHILADELPHIA · PI FORREST, CHRISTOPHER B, MOON, JEANHEE · 2018 to 2022
$4.0M
AHRQ HHS K12 HS026393NIAID NIH HHS U19 AI144301
6 · The paper itself

Abstract

purpose of reviewOver the course of the coronavirus disease 2019 (COVID-19) pandemic, it has become clear that the clinical features, epidemiology, and outcomes of COVID-19 are distinct in children relative to adults. In this review, we will present recent pediatric studies informing our current understanding of COVID-19 in children, and review pediatric considerations surrounding disease transmission, currently available therapies, and vaccination. RECENT

findingsRecent studies have shed light on the clinical epidemiology of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in children, identifying a high prevalence of asymptomatic and mild infections, with severe COVID-19 infrequently reported. Several adult clinical trials have informed the use of remdesivir, anti-SARS-CoV-2 monoclonal antibodies, dexamethasone, and tocilizumab in the management of COVID-19. Associations between underlying comorbid medical conditions and severe outcomes, as well as transmission dynamics of SARS-CoV-2 in children, are complex and warrant further study. Finally, highly efficacious vaccines are available for adults and adolescents, with pediatric trials ongoing. SUMMARY: Children generally fare well with acute COVID-19 infection, though critical illness is possible. Future research should focus on clarifying the role of children in SARS-CoV-2 transmission and optimal prevention strategies, particularly in the school setting, as well as evaluating pediatric vaccine candidates.

Indexed as

COVID-19 Drug TreatmentAntiviral AgentsChildHumansPandemicsSARS-CoV-2Antiviral Agents

Identifiers

PMID34261902
PMCPMC13671462
OpenAlexW3182470994

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.